article thumbnail

Pharmapack Europe Awards 2023 winners announced

European Pharmaceutical Review

The winners of Pharmapack Europe’s 2023 awards have been announced, presented across a range of innovative recyclable packaging, drug delivery solutions, and reusable connected devices. Three categories were available for entry in the Exhibitor Innovations section.

article thumbnail

Breathing easy: How digital inhalers are changing asthma treatment

Pharmaceutical Technology

But in recent years, the scope for these devices has expanded into digital inhaler platforms, presenting a way to potentially change how people with asthma and chronic obstructive pulmonary disease (COPD) manage their conditions. Enhancing the patient experience Today, digital inhalers are no longer limited to medication delivery.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Rytary (Carbidopa-Levodopa ER) in Parkinson’s Disease

Med Ed 101

Parkinson’s disease (PD) has long presented challenges in medication delivery. A staple in more advanced disease control, carbidopa-levodopa requires multiple daily dosing with supratherapeutic levels leading to dyskinesias and subtherapeutic concentrations leading to troublesome “off” time.

article thumbnail

Medication Safety Projects

FADIC

Monitoring: Ongoing evaluation of medication processes to identify issues early and rectify them. Feedback & Improvement: Using data, feedback loops, and collaboration across departments to continually refine and improve the medication delivery system. Promotion of interdisciplinary collaboration through platforms.

article thumbnail

Havas Health & You launches Behind the Mask

pharmaphorum

When interviewees are revisited over time and their views are accompanied by quantitative accounts, the story gains clarity and it becomes increasingly possible to present key moments in time in modern health. “We

article thumbnail

Pharma’s post-pandemic launch performance problem: what’s the prognosis?

pharmaphorum

Backlogs and reluctance of patients to present for diagnosis still linger, and for some disease areas a proportion of sufferers may never be diagnosed and treated, or may never be treated with the most recent launches. Launch opportunity is reduced. To thrive, companies need to plan their launches with different focus.